The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10491 malaria professionals are enjoying the free benefits of MalariaWorld today

Plasmodium vivax

Plasmodium vivax AMA1: Implications of distinct haplotypes for immune response

July 9, 2020 - 08:45 -- Open Access
Author(s): 
Bittencourt NC, da Silva ABIE, Albrecht L, et al.
Reference: 
PLoS Negl Trop Dis 14(7): e0008471

In Brazil, Plasmodium vivax infection accounts for around 80% of malaria cases. This infection has a substantial impact on the productivity of the local population as the course of the disease is usually prolonged and the development of acquired immunity in endemic areas takes several years. The recent emergence of drug-resistant strains has intensified research on alternative control methods such as vaccines.

NOT Open Access | The extent of chloroquine underdosing in adult patients with malaria by Plasmodium vivax from an endemic area of the Brazilian Amazon basin

July 8, 2020 - 15:42 -- NOT Open Access
Author(s): 
Valéria Dias Ferreira M, Gabryelle Nunes Cardoso Mello A, Wendel Pereira de Sena L, Regina Matos Lopes T, Luiz Fernandes Vieira J
Reference: 
Trop Med Int Health. 2020 Jul 7

To evaluate the extent of chloroquine underdosing and to measure the concentrations of chloroquine and desethylchloroquine in adult patients with P. vivax malaria in the Brazilian Amazon basin.

Molecular variation of Plasmodium vivax dehydrofolate reductase in Mexico and Nicaragua contrasts with that occurring in South America

July 8, 2020 - 15:32 -- Open Access
Author(s): 
González-Cerón L, Rodríguez MH, Montoya A, Santillán-Valenzuela F, Corzo-Gómez JC
Reference: 
Salud Publica Mex. 2020 Jul-Aug;62(4):364-371

To research mutations associated to pyrimethamine resistance in dihydrofolate reductase (pvdhfr) of Plasmodium vivax from Mexico and Nicaragua and compare it to that reported in the rest of America.

COVID-19: Possible Cause of Induction of Relapse of Plasmodium vivax Infection

July 7, 2020 - 13:11 -- Open Access
Author(s): 
Kishore R, Dhakad S, Arif N, Dar L, Mirdha BR, Aggarwal R, Kabra SK
Reference: 
Indian J Pediatr. 2020 Jul 3:1-2

To the Editor: In ongoing pandemic of novel corona virus disease (COVID-19), clinicians are observing atypical manifestations of the disease.

Insights into the molecular diversity of Plasmodium vivax merozoite surface protein-3γ (pvmsp3γ), a polymorphic member in the msp3 multi-gene family

July 7, 2020 - 13:07 -- Open Access
Author(s): 
Kuamsab N, Putaporntip C, Pattanawong U, Jongwutiwes S
Reference: 
Sci Rep. 2020 Jul 3;10(1):10977

Plasmodium vivax merozoite surface protein 3 (PvMSP3) is encoded by a multi-gene family. Of these, PvMSP3α, PvMSP3β and PvMSP3γ, are considered to be vaccine targets. Despite comprehensive analyses of PvMSP3α and PvMSP3β, little is known about structural and sequence diversity in PvMSP3γ. Analysis of 118 complete pvmsp3γ sequences from diverse endemic areas of Thailand and 9 reported sequences has shown 86 distinct haplotypes.

NOT Open Access | The comparison of Real-time-PCR-HRM and Microscopy Methods for Detection of Mixed Plasmodium spp. Infections in Laghman Province, Afghanistan

July 6, 2020 - 16:44 -- NOT Open Access
Author(s): 
Dalimi A, Mosawi SH
Reference: 
Infect Disord Drug Targets. 2020 Jul 2

Laghman province, in the east of the Afghanistan, is one of the most malaria endemic regions with an eminence of Plasmodium vivax and Plasmodium falciparum. So far, no study has been conducted to investigate the extent of mixed infections in this area.

NOT Open Access | Prevalence of Glucose 6-Phosphate Dehydrogenase Variants in Malaria-Endemic Areas of South Central Timor, Eastern Indonesia

July 1, 2020 - 16:33 -- NOT Open Access
Author(s): 
Sulistyaningrum N, Arlinda D, Chaijaroenkul W, et al.
Reference: 
Am J Trop Med Hyg. 2020 Jun 29

Primaquine is an effective anti-hypnozoite drug for Plasmodium vivax and Plasmodium ovale. However, it can trigger erythrocyte hemolysis in people with glucose 6-phosphate dehydrogenase (G6PD) deficiency. In a previous report from South Central Timor (SCT), Indonesia, we described the prevalence of Vanua Lava, Chatham, and Viangchan variants; in this study, other G6PD variants (Kaiping, Coimbra, Gaohe, Canton, and Mahidol) were subsequently analyzed. For clarity, all of these results are described together.

Presence of additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern Nigeria

June 30, 2020 - 14:18 -- Open Access
Author(s): 
Mary Aigbiremo Oboh, Upasana Shyamsunder Singh, Daouda Ndiaye, Aida Sadikh Badiane, Nazia Anwar Ali, Praveen Kumar Bharti and Aparup Das
Reference: 
Malaria Journal 2020 19:229, 26 June 2020

Malaria in sub-Saharan Africa (sSA) is thought to be mostly caused by Plasmodium falciparum. Recently, growing reports of cases due to Plasmodium ovale, Plasmodium malariae, and Plasmodium vivax have been increasingly observed to play a role in malaria epidemiology in sSA. This in fact is due to the usage of very sensitive diagnostic tools (e.g. PCR), which have highlighted the underestimation of non-falciparum malaria in this sub-region. Plasmodium vivax was historically thought to be absent in sSA due to the high prevalence of the Duffy negativity in individuals residing in this sub-continent. Recent studies reporting detection of vivax malaria in Duffy-negative individuals from Mali, Mauritania, Cameroon challenge this notion.

Plasmodium vivax liver stage assay platforms using Indian clinical isolates

June 26, 2020 - 15:14 -- Open Access
Author(s): 
Pradeep A. Subramani, Neha Vartak-Sharma, Varadharajan Sundaramurthy, et al.
Reference: 
Malaria Journal 2020 19:214, 22 June 2020

Vivax malaria is associated with significant morbidity and economic loss, and constitutes the bulk of malaria cases in large parts of Asia and South America as well as recent case reports in Africa. The widespread prevalence of vivax is a challenge to global malaria elimination programmes. Vivax malaria control is particularly challenged by existence of dormant liver stage forms that are difficult to treat and are responsible for multiple relapses, growing drug resistance to the asexual blood stages and host-genetic factors that preclude use of specific drugs like primaquine capable of targeting Plasmodium vivax liver stages. Despite an obligatory liver-stage in the Plasmodium life cycle, both the difficulty in obtaining P. vivax sporozoites and the limited availability of robust host cell models permissive to P. vivax infection are responsible for the limited knowledge of hypnozoite formation biology and relapse mechanisms, as well as the limited capability to do drug screening. Although India accounts for about half of vivax malaria cases world-wide, very little is known about the vivax liver stage forms in the context of Indian clinical isolates.

A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of Plasmodium vivax Induces High Antibody Titers and T-cells and Partially Protects Mice Challenged with a Transgenic Plasmodium berghei Parasite

June 23, 2020 - 15:39 -- Open Access
Author(s): 
Lima LC, Marques RF, Gimenez AM, Françoso KS, Aliprandini E, Camargo TM, Aguiar ACC, Pereira DB, Renia L, Amino R, Soares IS
Reference: 
Microorganisms 2020, 8(6), 916

Infections with Plasmodium vivax are predominant in the Americas, representing 75% of malaria cases. Previously perceived as benign, malaria vivax is, in fact, a highly debilitating and economically important disease. Considering the high complexity of the malaria parasite life cycle, it has been hypothesized that an effective vaccine formulation against Plasmodium should contain multiple antigens expressed in different parasite stages.

Pages

Subscribe to RSS - Plasmodium vivax